finance
Pomerantz Files Class Action Against Regencell Bioscience Holdings Limited
A securities class action lawsuit was filed against Regencell Bioscience Holdings Limited and certain officers in the U.S. District Court for the District of Maryland. The suit covers purchases made between October 28, 2024 and October 31, 2025.
May 26, 3:54 PM·1m read1 source
upi.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Pomerantz LLP announced that a class action lawsuit has been filed against Regencell Bioscience Holdings Limited and certain officers. The complaint was filed in the United States District Court for the District of Maryland under docket number 26-cv-01602.
The class consists of all persons and entities, other than defendants, that purchased or acquired Regencell securities between October 28, 2024 and October 31, 2025. Plaintiffs seek damages under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.
Investors who purchased Regencell securities during the class period have until June 23, 2026 to ask the court to appoint them as lead plaintiff. com. Contact information for inquiries is provided: Danielle Peyton at [email protected] or 646-581-9980 (or 888-4-POMLAW), toll-free, extension 7980.
Limited describes itself as an early-stage bioscience company focused on traditional Chinese medicine for attention-deficit/hyperactivity disorder and autism spectrum disorder. The company states that its TCM formulas aim to treat the fundamental cause of these neurocognitive disorders.
Regencell is designated a controlled company under Nasdaq Capital Market rules. 8 percent of its shares were held by controlling interests, according to its most recent annual report on Form 20-F.
